Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jan;98(1):4-6.
doi: 10.1038/labinvest.2017.129.

Cholecystectomy: a way forward and back to metabolic syndrome?

Gabriella Garruti  1 , David Q-H Wang  2 , Agostino Di Ciaula  3 , Piero Portincasa  4
Affiliations
Editorial

Cholecystectomy: a way forward and back to metabolic syndrome?

Gabriella Garruti et al. Lab Invest. 2018 Jan.

Abstract

The gallbladder provides rhythmic secretion of concentrated bile acids (BAs) during fasting and postprandially contributes to digestion of dietary lipids. In addition, BAs activate metabolic pathways governing gluco-lipid homeostasis and energy expenditure via the farnesoid X nuclear receptor (FXR), G protein-coupled BA receptor 1 (GPBAR-1), and fibroblast growth factor 19 (FGF19) in the liver, intestine, brown fat, and muscle. Cholecystectomy is standard treatment worldwide for symptomatic gallstone patients. As excellently reviewed by Chen et al, cholecystectomy may disrupt enterohepatic recycling of, and signaling by, BAs. Further studies are needed to investigate whether gallbladder removal is an independent risk factor for development of the metabolic syndrome.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE/CONFLICT OF INTEREST

The authors declare no conflict of interest.

References

    1. Lammert F, Acalovschi M, Ercolani G, et al. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016;65:146–181. - PubMed
    1. Chen Y, Wu S, Tian Y. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. Lab Invest 2017; doi: 10.1038/labinvest.2017.95. - DOI - PubMed
    1. Chavez-Talavera O, Tailleux A, Lefebvre P, et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 2017;152:1679–1694 e1673. - PubMed
    1. Vitek L, Haluzik M. The role of bile acids in metabolic regulation. J Endocrinol 2016;228:R85–R96. - PubMed
    1. Grundy SM. Cholesterol gallstones: a fellow traveler with metabolic syndrome? Am J Clin Nutr 2004;80:1–2. - PubMed

Publication types

MeSH terms